Investors
& Media

Jade Biosciences is focused on developing innovative, best-in-class therapies to address critical unmet needs in autoimmune diseases.

Our lead candidate, JADE101, targets the anti-APRIL (A Proliferation-Inducing Ligand) pathway for the treatment of immunoglobin A nephropathy (IgAN), a chronic kidney disease that can impair kidney function over time. JADE101 aims to reduce harmful IgA antibodies, lower proteinuria (a key marker of kidney damage), and preserve long-term kidney function. A first-in-human clinical trial is expected to begin in the second half of 2025, with interim biomarker-rich data anticipated in early 2026.

Jade’s pipeline also includes a second development candidate, JADE201, and an undisclosed antibody discovery program, JADE-003, both currently in preclinical development. See our pipeline to learn more.